A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of Single Doses of SHR4640 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2017
At a glance
- Drugs SHR 4640 (Primary)
- Indications Gout
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 26 Feb 2017 Status changed from recruiting to completed.
- 07 Jul 2016 New trial record